Destroying tumors while sparing healthy tissue is a key challenge in cancer research.
Radioisotopes show promising potential in selectively attacking tumors.
The radiopharmaceutical space, though historically lagging, is now gaining traction with new developments and interest from large pharmaceutical companies.